Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDA, BLA Submissions Expected To Fall Again in FY 2011

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA estimates that the number of fee-paying applications will continue to decline, meaning the user fee itself will increase more than 19% to $1.842 million for applications requiring clinical data.

You may also be interested in...



FDA Sees Another Submission Decrease In FY 2011, Increases Application Fees

The figures continue a recent trend of decreases in fee-paying full application equivalents but were not as low as had been estimated.

FDA Sees Another Submission Decrease In FY 2011, Increases Application Fees

The figures continue a recent trend of decreases in fee-paying full application equivalents but were not as low as had been estimated.

User Fee Triggers Require Care In Unfriendly Budget Environment, Ventimiglia Says

Trigger changes could feed argument that user fees are a tax on industry.

Related Content

Topics

UsernamePublicRestriction

Register

PS072618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel